|
|
The New England Journal of Medicine Publishes Results from the Phase 3 HARMONY Study Evaluating Pimavanserin in Patients with Dementia-Related Psychosis
|
|
|
Acadia Pharmaceuticals to Announce Second Quarter 2021 Financial Results on August 4, 2021
|
|
|
Acadia Pharmaceuticals to Present New Scientific Data on Pimavanserin in Neurodegenerative Diseases at the Alzheimer’s Association International Conference 2021 (AAIC)
|
|
|
NUPLAZID® (pimavanserin) Efficacy Data from Open-Label Extension (OLE) Study Published in Parkinsonism and Related Disorders
|
|
|
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results
|
|
|
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
Acadia Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021
|
|
|
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
|
|
|
Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis
|
|
|
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
|
|
|
Acadia Pharmaceuticals Recognizes National Caregiver’s Day with Launch of MoreThanMemoryLoss.com
|
|
|
Acadia Pharmaceuticals to Present at Upcoming Investor Conferences
|
|
|
Acadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
|
|
|
Acadia Pharmaceuticals Announces Commercial Leadership Change
|
